Key result
Prothrombic mutations (FV Leiden, prothrombin G20210A, MTHFR C677T) were not associated with left ventricular thrombus, showing similar allele frequencies in patients with vs without thrombus.
Why the study?
Does the presence of thrombophilic mutations (FV Leiden, prothrombin G20210A, MTHFR C677T) increase the risk of left ventricular thrombus in patients with acute myocardial infarction?
Observational (n=183)
Does the presence of thrombophilic mutations (FV Leiden, prothrombin G20210A, MTHFR C677T) increase the risk of left ventricular thrombus in patients with acute myocardial infarction?
Common thrombophilic mutations (FV Leiden, prothrombin G20210A, MTHFR C677T) are not associated with an increased risk of developing a left ventricular thrombus following an anterior acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Does not support thrombophilia screening to predict LV thrombus after anterior MI; leaves open contributions of other factors.
OBJECTIVE: Within the last few years a number of thrombophilic mutations have been identified. Pre-symptomatic testing for these established genetic risk factors identifies individuals predisposed to a disease and often allows to select suitable prophylactic interventions in time. We investigated whether or not the prothrombin G20210A allele, the factor V Leiden G1691A, and MTHFR C677T allele are risk factors for left ventricular thrombus (LV) in patients with myocardial infarction (AMI) or not. METHODS AND RESULTS: We analysed clinical, echocardiographic and biochemical data in 183 consecutive patients (aged 58 +/- 12 years; 34 women) with a first anterior acute myocardial infarction. Two-dimensional echocardiographic examination was performed on days 1, 3, 7, 15, and 30. LV thrombi were detected in 42 (23%) of the 183 patients with acute myocardial infarction. We have used multiplex assays based on PCR and DNA hybridization in microtitre plates for the simultaneous analysis of three mutations (FV Leiden G1691A, prothrombin G20210A, and MTHFR C677T). No significant differences in allele frequencies of FV Leiden G1691A (9.5% vs. 8.5%, p = 0.75), prothrombin G20210A (9.5% vs 7.1%, p = 0.74) and MTHFR C677T (47.6% vs. 50.3%, p = 0.74) were found in patients with LV thrombus when compared with those without LV thrombus. No significant differences in haemostatic factor levels were found in patients with LV thrombus when compared with those without LV thrombus. CONCLUSION: FV Leiden, prothrombin 20210 variant, and MTHFR mutation are no risk factors for left ventricular thrombus in patients with myocardial infarction.The presence of multiple mutations did not influence the development and outcome of LV thrombus in patients with myocardial infarction
No takes yet. Share an insight, caveat, or question.
Uçar et al. (2004) conducted an observational in First anterior acute myocardial infarction (n=183). Prothrombic mutations (FV Leiden G1691A, prothrombin G20210A, MTHFR C677T) vs. Absence of mutations was evaluated on Left ventricular thrombus. Prothrombic mutations (FV Leiden, prothrombin G20210A, MTHFR C677T) were not associated with left ventricular thrombus, showing similar allele frequencies in patients with vs without thrombus.
Synapse has enriched 10 related papers. Consider them for comparative context: